American Journal of Kidney Diseases · 2017 · 143 citations · 39 references
MedicineNephrologySurgeryDialysisHemodialysisRenal Replacement TherapyDialysis AccessDialysis Vascular AccessEndovascular SurgeryVascular AccessVascular Access SafetyVascular AnastomosisArteriovenous Fistula CannulationHemodialysis Access CreationHemodialysis Vascular Access SafetyPercutaneous Fistula CreationPrescribed Dialysis DoseVascular Access CreationVascular Access FunctionVascular Access Patency
BackgroundHemodialysis arteriovenous fistulas (AVFs) are suboptimally used primarily due to problems with maturation, early thrombosis, and patient nonacceptance. An endovascular approach to fistula creation without open surgery offers another hemodialysis vascular access option.Study DesignProspective, single-arm, multicenter study (Novel Endovascular Access Trial [NEAT]).Settings & ParticipantsConsecutive adult non−dialysis-dependent and dialysis-dependent patients referred for vascular access creation at 9 centers in Canada, Australia, and New Zealand.InterventionUsing catheter-based endovascular technology and radiofrequency energy, an anastomosis was created between target vessels, resulting in an endovascular AVF (endoAVF).OutcomesSafety, efficacy, functional usability, and patency end points.MeasurementsSafety as percentage of device-related serious adverse events; efficacy as percentage of endoAVFs physiologically suitable (brachial artery flow ≥ 500 mL/min, vein diameter ≥ 4 mm) for dialysis within 3 months; functional usability of endoAVFs to provide prescribed dialysis via 2-needle cannulation; primary and cumulative endoAVF patencies per standardized definitions.Results80 patients were enrolled (20 roll-in and 60 participants in the full analysis set; the latter are reported). EndoAVFs were created in 98% of participants; 8% had a serious procedure-related adverse event (2% device related). 87% were physiologically suitable for dialysis (eg, mean brachial artery flow, 918 mL/min; endoAVF vein diameter, 5.2 mm [cephalic vein]). EndoAVF functional usability was 64% in participants who received dialysis. 12-month primary and cumulative patencies were 69% and 84%, respectively.LimitationsDue to the unique anatomy and vessels used to create endoAVFs, this was a single-arm study without a surgical comparator.ConclusionsAn endoAVF can be reliably created using a radiofrequency magnetic catheter-based system, without open surgery and with minimal complications. The endoAVF can be successfully used for hemodialysis and demonstrated high 12-month cumulative patencies. It may be a viable alternative option for achieving AVFs for hemodialysis patients in need of vascular access. Hemodialysis arteriovenous fistulas (AVFs) are suboptimally used primarily due to problems with maturation, early thrombosis, and patient nonacceptance. An endovascular approach to fistula creation without open surgery offers another hemodialysis vascular access option. Prospective, single-arm, multicenter study (Novel Endovascular Access Trial [NEAT]). Consecutive adult non−dialysis-dependent and dialysis-dependent patients referred for vascular access creation at 9 centers in Canada, Australia, and New Zealand. Using catheter-based endovascular technology and radiofrequency energy, an anastomosis was created between target vessels, resulting in an endovascular AVF (endoAVF). Safety, efficacy, functional usability, and patency end points. Safety as percentage of device-related serious adverse events; efficacy as percentage of endoAVFs physiologically suitable (brachial artery flow ≥ 500 mL/min, vein diameter ≥ 4 mm) for dialysis within 3 months; functional usability of endoAVFs to provide prescribed dialysis via 2-needle cannulation; primary and cumulative endoAVF patencies per standardized definitions. 80 patients were enrolled (20 roll-in and 60 participants in the full analysis set; the latter are reported). EndoAVFs were created in 98% of participants; 8% had a serious procedure-related adverse event (2% device related). 87% were physiologically suitable for dialysis (eg, mean brachial artery flow, 918 mL/min; endoAVF vein diameter, 5.2 mm [cephalic vein]). EndoAVF functional usability was 64% in participants who received dialysis. 12-month primary and cumulative patencies were 69% and 84%, respectively. Due to the unique anatomy and vessels used to create endoAVFs, this was a single-arm study without a surgical comparator. An endoAVF can be reliably created using a radiofrequency magnetic catheter-based system, without open surgery and with minimal complications. The endoAVF can be successfully used for hemodialysis and demonstrated high 12-month cumulative patencies. It may be a viable alternative option for achieving AVFs for hemodialysis patients in need of vascular access.
39
Effect of Clopidogrel on Early Failure of Arteriovenous Fistulas for Hemodialysis
Laura M. Dember, Gerald J. Beck, Michael Allon et al. · JAMA · 2008 · 817 citations · Full text
Hemodialysis Arteriovenous Fistula Maturity: US Evaluation
Michelle L. Robbin, Nathan E. Chamberlain, Mark E. Lockhart et al. · Radiology · 2002 · 480 citations
Medicine, Nephrology, Dialysis +16
Hemodialysis Arteriovenous Fistula Patency Revisited
H.J.T.A.M. Huijbregts, Michiel L. Bots, C.H.A. Wittens et al. · Clinical Journal of the American Society of Nephrology · 2008 · 352 citations · Full text
Medicine, Nephrology, Dialysis +16